VasoRx is leading the translation of technologies discovered at M.I.T. and Yale for the delivery of RNAs for the treatment of diseases. With the first approved RNAi therapeutic in the U.S., the field of RNA medicines is rapidly expanding. Delivery of these new medicines has been a major challenge, and most of the RNA pipeline therapies utilize nanoparticle technology that targets the liver. Hence, many of the products in the pipeline are targeting liver diseases.
VasoRx utilizes novel nanoparticles that preferentially target the endothelium, dramatically expanding the opportunities for developing RNA therapies for diseases of the cardiovascular system as well as oncology.